Actinium Pharmaceuticals, Inc. announced that Dr. Mark Berger has been appointed Chief Medical Officer Effect from January 18, 2017. Dr. Berger joins Actinium with significant drug development expertise that includes the planning and execution of clinical trials that led to the FDA approval of Mylotarg for acute myeloid leukemia while at Wyeth Research and Tykerb for breast cancer while at GlaxoSmithKline. Dr. Berger will report to Sandesh Seth, Actinium’s Executive Chairman. Dr. Berger previously served as Group Director, Medicine Development Centre-Oncology for GlaxoSmithKline. Dr. Dragan Cicic, Actinium’s previous Chief Medical Officer, has been appointed to the newly created position of Chief Technology Officer. In his new role, Dr. Cicic will be responsible for leveraging Actinium’s alpha particle immunotherapy (APIT) technology platform to further expand Actinium’s clinical pipeline. Dr. Cicic will also be responsible for driving strategic initiatives including research collaborations and partnerships as well as continuing to expand relationships with the medical and scientific communities.